| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
185,611,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
6,246,627 |
Avg
Vol: |
2,897,741 |
| 52
Week Range: |
$23.99 - $23.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Duvall Martin J |
EVP, CCO |
• • – |
2016-03-03 |
4 |
AS |
$6.12 |
$58,863 |
D/D |
(9,625) |
89,039 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2016-03-03 |
4 |
AS |
$6.12 |
$58,867 |
D/D |
(9,625) |
334,630 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2016-03-03 |
4 |
AS |
$6.12 |
$58,869 |
D/D |
(9,625) |
132,742 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2016-03-03 |
4 |
AS |
$6.11 |
$58,852 |
D/D |
(9,625) |
151,088 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2016-03-03 |
4 |
AS |
$6.11 |
$64,733 |
D/D |
(10,588) |
144,086 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2016-03-02 |
4 |
AS |
$6.00 |
$150,282 |
D/D |
(25,047) |
344,255 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2016-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,250 |
324,576 |
|
- |
|
| Berstein David L |
SVP, Chief IP Counsel |
• • – |
2016-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,250 |
269,365 |
|
- |
|
| Duvall Martin J |
EVP, CCO |
• • – |
2016-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,250 |
98,664 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2016-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,250 |
369,302 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2016-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,250 |
142,367 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2016-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,250 |
160,713 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2016-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,250 |
154,674 |
|
- |
|
| Lamarche Jay R |
Director |
• • – |
2016-02-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
12,500 |
552,205 |
|
- |
|
| Schlesinger Sarah J. |
Director |
• • – |
2016-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
37,500 |
|
- |
|
| Wilson Wayne |
Director |
• • – |
2016-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
125,500 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2016-02-01 |
4 |
AS |
$4.81 |
$77,587 |
D/D |
(16,133) |
135,424 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,333 |
151,557 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2016-02-01 |
4 |
AS |
$4.81 |
$77,745 |
D/D |
(16,133) |
123,117 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,333 |
139,250 |
|
- |
|
| Berstein David L |
SVP, Chief IP Counsel |
• • – |
2016-02-01 |
4 |
AS |
$4.81 |
$70,515 |
D/D |
(14,667) |
250,115 |
|
- |
|
| Berstein David L |
SVP, Chief IP Counsel |
• • – |
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,333 |
264,782 |
|
- |
|
| Lamarche Jay R |
Director |
• • – |
2016-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
452,205 |
|
- |
|
| Radaelli Massimo |
Director |
• • – |
2016-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
105,500 |
|
- |
|
| Duvall Martin J |
EVP, CCO |
• • – |
2016-02-01 |
4 |
AS |
$4.81 |
$70,578 |
D/D |
(14,667) |
79,414 |
|
- |
|
703 Records found
|
|
Page 2 of 29 |
|
|
